Do Disease-Modifying Anti-rheumatic Drugs and Exercise Therapy Have a Combined Effect on Disease Activity in Patients with RA? A Scoping Review

被引:0
|
作者
Sobejana, M. [1 ]
van der Esch, M. [1 ,2 ]
van den Hoek, J. [1 ]
Kitas, G. [3 ,4 ]
van der Leeden, M. [1 ,5 ]
Nurmohamed, M. T. [1 ,6 ]
Metsios, G. S. [7 ]
机构
[1] Amsterdam Rehabil Res Ctr, Ctr Rehabil & Rheumatol, POB 58271, NL-1040 HG Amsterdam, Netherlands
[2] Amsterdam Univ Appl Sci, Fac Hlth, Ctr Expertise Urban Vital, Amsterdam, Netherlands
[3] Russells Hall Hosp, Dudley Grp NHS Fdn Trust, Clin Res Unit, Dudley, England
[4] Univ Birmingham, Sch Sports & Exercise Sci, Birmingham, England
[5] Vrije Univ, Amsterdam Univ, Dept Rehabil Med, Med Ctr,Amsterdam Movement Sci Res Inst, Amsterdam, Netherlands
[6] Univ Amsterdam, Med Ctr, Dept Rheumatol, Amsterdam, Netherlands
[7] Univ Thessaly, Dept Nutr & Dietet, Trikala, Thessaly, Greece
关键词
Rheumatoid arthritis; Anti-rheumatic drug treatment; DMARDs; Exercise; DAS; RHEUMATOID-ARTHRITIS; CARDIORESPIRATORY FITNESS; STRENGTH; CACHEXIA; PROGRAM; MUSCLE; RISK;
D O I
10.1007/s11926-023-01098-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose of Review In addition to disease-modifying anti-rheumatic drug (DMARD) treatment, exercise is increasingly promoted in patients with rheumatoid arthritis (RA). Although both are known to reduce disease activity, few studies have investigated the combined effects of these interventions on disease activity. The aim of this scoping review was to provide an overview of the reported evidence on whether a combined effect-i.e., a greater reduction in disease activity outcome measures-can be detected in studies where an exercise intervention was performed in addition to the DMARD treatment in patients with RA. This scoping review followed the PRISMA guidelines. A literature search was performed for exercise intervention studies in patients with RA treated with DMARDs. Studies without a non-exercise control group were excluded. Included studies reported on (components of) DAS28 and DMARD use and were assessed for methodological quality using version 1 of the Cochrane risk-of-bias tool for randomized trials. For each study, comparisons between groups (i.e., exercise + medication vs. medication only) were reported on disease activity outcome measures. Study data related to the exercise intervention, medication use, and other relevant factors were extracted to assess what may have influenced disease activity outcomes in the included studies. Recent Findings A total of 11 studies were included of which 10 between-group studies on DAS28 components were made. The remaining one study focused on within-group comparisons only. Median duration of the exercise intervention studies was 5 months, and the median number of participants was 55. Six out of the 10 between-group studies reported no significant differences between groups in DAS28 components between exercise + medication vs. medication only. Four studies showed significant reductions in disease activity outcomes for the exercise + medication group compared with the medication-only group. Most studies were not adequately designed methodologically in order to investigate for comparisons of DAS28 components and had a high risk of multi-domain bias. Whether the simultaneous application of exercise therapy and DMARD medication in patients with RA has a combined effect on disease outcome remains unknown, due to weak methodological quality of existing studies. Future studies should focus on the combined effects by having disease activity as the primary outcome.
引用
收藏
页码:69 / 81
页数:13
相关论文
共 50 条
  • [31] Cardiovascular Effects of Biologic Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
    Drakopoulou, Maria
    Soulaidopoulos, Stergios
    Oikonomou, George
    Tousoulis, Dimitrios
    Toutouzas, Konstantinos
    CURRENT VASCULAR PHARMACOLOGY, 2020, 18 (05) : 488 - 506
  • [32] Assessment of adherence to disease-modifying anti-rheumatic drugs in rheumatoid arthritis
    Clélia Monchablon
    Henri Gondé
    Sophie Pouplin
    Rémi Varin
    Olivier Vittecoq
    Thierry Lequerré
    Clinical Rheumatology, 2020, 39 : 207 - 216
  • [33] Malignancies in spondyloarthritis with and without concomitant psoriasis, and the effect of disease-modifying anti-rheumatic drugs
    Chung, H. Y.
    Chan, S. C. W.
    Chui, E. T. F.
    Yau, T.
    Lau, C. S.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2022, 40 (05) : 913 - 920
  • [34] Utilization of biologic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis and cancer
    Xerxes Pundole
    Natalia V. Zamora
    Harish Siddhanamatha
    Heather Lin
    Jean Tayar
    Leung Cheuk Hong
    Liang Li
    Maria E. Suarez-Almazor
    Clinical Rheumatology, 2020, 39 : 787 - 794
  • [35] Use of disease-modifying anti-rheumatic drugs and cardiovascular events in patients with rheumatoid arthritis
    Kaminski, Matthew
    Shishehbor, Mehdi H.
    Gutierrez, Antonio
    Amini, Mohammad R.
    Coats, Walter
    Moghbelli, Meisam
    Askari, Arman T.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 51 (10) : A370 - A370
  • [36] Utilization of biologic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis and cancer
    Pundole, Xerxes
    Zamora, Natalia V.
    Siddhanamatha, Harish
    Lin, Heather
    Tayar, Jean
    Hong, Leung Cheuk
    Li, Liang
    Suarez-Almazor, Maria E.
    CLINICAL RHEUMATOLOGY, 2020, 39 (03) : 787 - 794
  • [37] Effect of disease-modifying anti-rheumatic drugs on therapeutic outcomes among women with endometriosis
    Kotlyar, Alexander
    Shue, Shirley
    Liu, Xiaobo
    Falcone, Tommaso
    INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2018, 141 (02) : 228 - 233
  • [38] Disease-modifying anti-rheumatic drugs improve the cardiovascular profile in patients with rheumatoid arthritis
    Giachi, Andrea
    Cugno, Massimo
    Gualtierotti, Roberta
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9
  • [39] A call for guidance on the treatment of patients taking disease-modifying anti-rheumatic drugs (DMARDs)
    Dickson, Kirsty Skye
    Regan, Alasdair
    Wemyss, Callum
    Paley, Martin
    Siddiqui, Arshad
    BRITISH JOURNAL OF ORAL & MAXILLOFACIAL SURGERY, 2024, 62 (04): : 389 - 390
  • [40] THE EFFECT OF BIOLOGICAL AND CONVENTIONAL DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS ON FATIGUE IN FIBROMYALGIC RHEUMATOID ARTHRITIS PATIENTS
    Hizmetli, S.
    Durmaz, Y.
    Kaptanoglu, E.
    Cengiz, A. K.
    Peksen, H.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 864 - 864